EUVIMEDEUVIMED entdecken
Crossref

BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis

Yahui Huang, Na Liu iD, Zhizhi Pan, Zhuang Li, Chunquan Sheng iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yahui Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of Chin…. Hauptthemen laut MEDLINE: Breast Neoplasms, Candidiasis, Anti-Infective Agents. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shanghai Municipal Education Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is susceptible to Candida infections, and candidiasis has an enhancing effect on the progression and metastasis of tumor. Breast cancer and concurrent candidiasis represent a significant challenge in clinical therapy. Herein, a series of novel small molecule inhibitors simultaneously targeting bromodomain and extra-terminal (BET) and histone deacetylase (HDAC) were designed for combinational treatment of breast cancer and resistant Candida albicans infections. Among them, compounds 13c and 17b exhibited excellent and balanced inhibitory activity against both BET family proteins BRD4 and HDAC1. As compared with BRD4 or HDAC1 inhibitors, dual inhibitors 13c and 17b displayed improved in vivo antitumor efficacy in MDA-MB-231 breast cancer xenograft models. Notably, they synergized with fluconazole (FLC) to effectively reduce the kidney fungal burden in a murine model of disseminated candidiasis. Thus, the BET-HDAC dual inhibitors represented a novel therapeutic strategy for combinational treatment of breast cancer and concurrent candidiasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCandidiasisAnti-Infective AgentsHumansMiceAnimalsFemaleHistone Deacetylase InhibitorsNuclear ProteinsCell Line, TumorTranscription FactorsCell Cycle ProteinsCarbon IsotopesBromodomain Containing Proteins

Substanzen

Histone Deacetylase InhibitorsNuclear ProteinsTranscription FactorsAnti-Infective AgentsCell Cycle ProteinsCarbon-13Carbon IsotopesBRD4 protein, humanBromodomain Containing Proteins

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China.
  • College of Pharmacy, Dali University, Xueren Road 2, Dali 671000, People's Republic of China.

ORCID-Profile: Na Liu, Chunquan Sheng

Förderung

  • Shanghai Municipal Education Commission
  • National Natural Science Foundation of China

Zitieren

APA

Huang, Y., Liu, N., Pan, Z., Li, Z., & Sheng, C. (2023). BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01191

Vancouver

Huang Y, Liu N, Pan Z, Li Z, Sheng C. BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01191

BibTeX
@article{Huang2023,
  author = {Huang, Yahui and Liu, Na and Pan, Zhizhi and Li, Zhuang and Sheng, Chunquan},
  title = {BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01191}
}
Kostenlos starten →